Edition:
India

Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

473.45INR
27 May 2016
Change (% chg)

Rs5.50 (+1.18%)
Prev Close
Rs467.95
Open
Rs470.90
Day's High
Rs478.50
Day's Low
Rs469.10
Volume
2,638,981
Avg. Vol
2,199,244
52-wk High
Rs745.00
52-wk Low
Rs457.45

CIPL.NS

Chart for CIPL.NS

About

Cipla Limited is a pharmaceutical company. The Company's business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company offers APIs, formulations and veterinary products. As of March 31, 2015, the Company offered its services across five continents across the world. It offers... (more)

Overall

Beta: 0.46
Market Cap(Mil.): Rs380,396.50
Shares Outstanding(Mil.): 803.46
Dividend: 2.00
Yield (%): 0.42

Financials

  CIPL.NS Industry Sector
P/E (TTM): 25.33 35.22 36.14
EPS (TTM): 18.69 -- --
ROI: 12.87 13.74 13.10
ROE: 13.29 14.88 14.37

Cipla Q4 profit lags due to one-off charges in Europe, emerging markets

MUMBAI Cipla Ltd, India's fifth-largest drugmaker by sales, reported a 69 percent fall in its quarterly profit, well below analysts' forecasts, due to one-off costs related to its business in Europe and some emerging markets.

24 May 2016

UPDATE 1-India's Cipla Q4 profit lags due to one-off charges in Europe, emerging markets

* Says exiting some emerging markets, modifying Europe business

24 May 2016

India drugmaker Cipla profit falls short of forecast, down 69 pct

MUMBAI, May 24 Cipla Ltd, India's fifth-largest drugmaker by sales, reported a fall of 69 percent in its quarterly earnings on Tuesday, far short of analysts' forecasts.

24 May 2016

BUZZ-India Cipla falls ahead of earnings; net income may miss estimates

** The pharmaceutical major will report Dec-qtr earnings later in the day

10 Feb 2016

Baxalta-Coherus Enbrel biosimilar succeeds in late-stage study

Baxalta Inc and Coherus Biosciences Inc said their experimental biosimilar of Amgen Inc's arthritis drug Enbrel met the main goal in a late-stage study.

11 Jan 2016

UPDATE 1-Baxalta-Coherus Enbrel biosimilar succeeds in late-stage study

Jan 11 Baxalta Inc and Coherus Biosciences Inc said their experimental biosimilar of Amgen Inc's arthritis drug Enbrel met the main goal in a late-stage study.

11 Jan 2016

Earnings vs. Estimates